• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » SafeStitch Medical to merge with TransEnterix, raise $30M

SafeStitch Medical to merge with TransEnterix, raise $30M

August 14, 2013 By Brad Perriello

SafeStitch Medical to merge with TransEnterix, raise $30M

SafeStitch Medical (OTC:SFES) and TransEnterix are set to merge next quarter in a deal that includes a private placement worth about $30 million.

Miami-based SafeStitch said the deal will see it move to Research Triangle, N.C., but keep its name, stock symbol and place on the OTC exchange. TransEnterix CEO Todd Pope will helm the new SafeStitch, with chairman (and medtech veteran) Paul LaViolette at the head of the new firm’s board. SafeStitch chairwoman Jane Hsiao will take a seat on the new entity’s board, with OPKO Health chairman Phillip Frost joining the board, according to a press release.

The release did not mention SafeStitch founder, president & CEO Jeffrey Spragens or detail any other management changes. A SafeStitch representative was not available for comment this afternoon.

The deal will see each share of TransEnterix stock converted into 1.1723 shares of the new SafeStitch, according to a regulatory filing. Shares held by non-accredited investors will be converted into cash, priced at the average SFES share price for the 60-trading day period before the merger closes. Shares were trading at 90¢ apiece as of about 2 p.m. today, down 2.2%.

The deal also calls for investors including Hsiao and Frost’s Frost Gamma Investments Trust to acquire 7.5 million preferred shares at $4 each, or about $30 million, in a private placement, according to the filing. Each share would convert to 10 shares of common stock, according to the filing.

After the deal closes, expected during the 3rd quarter, shareholders of SafeStitch Medical and TransEnterix will own approximately 35% and 65% of the combined company, respectively, SafeStitch said.

SafeStitch, founded in 2005 by Dr. Charles Filipi and Spragens, makes the Amid hernia fixation device. TransEnterix makes laparoscopic devices including the Spider and Starr instruments. It was founded in 2006 and raised $21 million in "institutional financing" in 2008, according to its website. Another $55 million round followed in 2009 and TransEnterix raised a further $15 million in venture capital backing in 2011.

"We believe this merger will significantly enhance our ability to bring our innovative robotic surgery platform to market. Drs. Frost and Hsiao have a proven track record of driving healthcare innovation while creating significant value for shareholders. We expect the company will be at the forefront of advancements in minimally invasive surgery," Pope said in prepared remarks.

"We are excited about the breadth of the management team of TransEnterix. There are compelling advantages to innovative flexible technologies and robotics for less invasive surgical interventions, such as our proprietary trans-oral device. This merger will provide greater resources to help bring the pipeline products of the combined company to market and offer our shareholders an excellent opportunity to realize significant value of their investment," Hsiao added.

Filed Under: Endoscopic, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Opko Health Inc., SafeStitch Medical, TransEnterix

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy